Allos Oncologic Efaproxiral Is “Approvable” Pending Phase III ENRICH Data
Executive Summary
Approval of Allos' oncologic efaproxiral will need to await positive data from an ongoing Phase III study in patients with brain metastases originating from breast cancer, an FDA "approvable" letter states
You may also be interested in...
Allos CEO resigns
Allos Therapeutics CEO and CFO Michael Hart will resign his positions following appointment of a successor CEO. During Hart's tenure, Allos received an "approvable" letter for Efaproxyn (efaproxiral) for use as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer (1"The Pink Sheet" June 7, 2004, p. 6). Hart joined Allos in 1999 as chief financial officer and senior VP-operations. He was promoted to president and CEO in December 2001, and appointed to the board of directors in April 2002...
Allos CEO resigns
Allos Therapeutics CEO and CFO Michael Hart will resign his positions following appointment of a successor CEO. During Hart's tenure, Allos received an "approvable" letter for Efaproxyn (efaproxiral) for use as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer (1"The Pink Sheet" June 7, 2004, p. 6). Hart joined Allos in 1999 as chief financial officer and senior VP-operations. He was promoted to president and CEO in December 2001, and appointed to the board of directors in April 2002...
Allos Efaproxiral ENRICH Data Needed For Brain Metastases Approval
Approval of Allos Therapeutics' oncologic Excelar (efaproxiral/RSR13) should await confirmatory efficacy data from an ongoing Phase III trial, an FDA advisory committee recommended May 3